These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 15984908)

  • 1. Preventing cardiovascular outcome in patients with renal impairment: is there a role for lipid-lowering therapy?
    Holdaas H
    Am J Cardiovasc Drugs; 2005; 5(4):255-69. PubMed ID: 15984908
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of lipid-lowering therapy on reduction of cardiovascular events in patients with end-stage renal disease requiring hemodialysis.
    Marrs JC; Saseen JJ
    Pharmacotherapy; 2010 Aug; 30(8):823-9. PubMed ID: 20653359
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cardiovascular disease in patients with chronic kidney disease. A clinical review.
    Kaisar M; Isbel N; Johnson DW
    Minerva Urol Nefrol; 2007 Sep; 59(3):281-97. PubMed ID: 17912225
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dyslipidaemia in chronic kidney disease.
    Krane V; Wanner C
    Minerva Urol Nefrol; 2007 Sep; 59(3):299-316. PubMed ID: 17912226
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical epidemiology of cardiovascular disease in chronic kidney disease.
    Kundhal K; Lok CE
    Nephron Clin Pract; 2005; 101(2):c47-52. PubMed ID: 15942250
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optimizing outcomes in patients with cardiovascular disease and chronic kidney disease.
    Marrs JC
    Am J Manag Care; 2011 Dec; 17 Suppl 15():S403-11. PubMed ID: 22214475
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ezetimibe as a potential treatment for dyslipidemia associated with chronic renal failure and renal transplant.
    Ahmed MH; Khalil AA
    Saudi J Kidney Dis Transpl; 2010 Nov; 21(6):1021-9. PubMed ID: 21060168
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lipid metabolism in chronic kidney disease: the role of statins in cardiovascular risk.
    Wanner C; Drechsler C; Krane V
    J Ren Nutr; 2007 Jan; 17(1):75-8. PubMed ID: 17198938
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Controversies Regarding Lipid Management and Statin Use for Cardiovascular Risk Reduction in Patients With CKD.
    Markossian T; Burge N; Ling B; Schneider J; Pacold I; Bansal V; Leehey D; Stroupe K; Chang A; Kramer H
    Am J Kidney Dis; 2016 Jun; 67(6):965-77. PubMed ID: 26943983
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Statin treatment for dyslipidemia in chronic kidney disease and renal transplantation: a review of the evidence.
    Kanbay M; Turgut F; Covic A; Goldsmith D
    J Nephrol; 2009; 22(5):598-609. PubMed ID: 19809992
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum Phosphorus and Risk of Cardiovascular Disease, All-Cause Mortality, or Graft Failure in Kidney Transplant Recipients: An Ancillary Study of the FAVORIT Trial Cohort.
    Merhi B; Shireman T; Carpenter MA; Kusek JW; Jacques P; Pfeffer M; Rao M; Foster MC; Kim SJ; Pesavento TE; Smith SR; Kew CE; House AA; Gohh R; Weiner DE; Levey AS; Ix JH; Bostom A
    Am J Kidney Dis; 2017 Sep; 70(3):377-385. PubMed ID: 28579423
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Hypertension, dyslipidemia and cardiovascular risk in chronic renal disease].
    Ravera M; Paoletti E
    Ital Heart J Suppl; 2004 Jun; 5(6):436-44. PubMed ID: 15471148
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dyslipidemia in chronic kidney disease: an approach to pathogenesis and treatment.
    Tsimihodimos V; Dounousi E; Siamopoulos KC
    Am J Nephrol; 2008; 28(6):958-73. PubMed ID: 18612199
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Statins and kidney disease].
    Bigazzi R; Grimaldi D; Bianchi S
    G Ital Nefrol; 2012; 29(2):160-73. PubMed ID: 22538946
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lipid lowering in dialysis patients with cardiovascular disease who are awaiting kidney transplantation.
    Aziz F; Garg N; Parajuli S; Djamali A; Stein JH; Mandelbrot D
    Clin Transplant; 2019 Jan; 33(1):e13452. PubMed ID: 30466167
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dyslipidaemia and cardiorenal disease: mechanisms, therapeutic opportunities and clinical trials.
    Chan DT; Irish AB; Dogra GK; Watts GF
    Atherosclerosis; 2008 Feb; 196(2):823-34. PubMed ID: 17343861
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lipid-Lowering Therapy in CKD: Should We Use It and in Which Patients.
    Kaysen GA
    Blood Purif; 2017; 43(1-3):196-199. PubMed ID: 28114129
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dyslipidemia treatment and cardiovascular disease in the renal patient.
    Burst V; Benzing T
    Curr Pharm Des; 2011; 17(9):894-907. PubMed ID: 21418028
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aspirin Use and Incident Cardiovascular Disease, Kidney Failure, and Death in Stable Kidney Transplant Recipients: A Post Hoc Analysis of the Folic Acid for Vascular Outcome Reduction in Transplantation (FAVORIT) Trial.
    Dad T; Tighiouart H; Joseph A; Bostom A; Carpenter M; Hunsicker L; Kusek JW; Pfeffer M; Levey AS; Weiner DE
    Am J Kidney Dis; 2016 Aug; 68(2):277-286. PubMed ID: 26947217
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dyslipidemia in chronic kidney disease: are statins still indicated in reduction cardiovascular risk in patients on dialysis treatment?
    Scarpioni R; Ricardi M; Melfa L; Cristinelli L
    Cardiovasc Ther; 2010 Dec; 28(6):361-8. PubMed ID: 20553296
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.